Company Registry

Balance Therapeutics Inc
Profile last edited on: 6/9/2016

Drug therapies for intellectual disability: Down's syndrome and Alzheimer’s disease.
Year Founded
First SBIR Year
Latest SBIR Award
Program Status


Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1250 Bayhill Drive Unit 125
San Bruno, CA 94066
Multiple Locations:   
Congressional District:   14
County:   San Mate

Public Profile

Balance Therapeutics, spun out of Stanford, is a R&D company focused on developing therapeutics to address conditions of intellectual disability to include Down syndrome and Alzheimer’s disease. The firm's pharmacological approach is based on technology licensed from Stanford University that has demonstrated promising potential to address cognitive deficits in animal models of Down syndrome and Alzheimer’s disease. Focused on the development of BTD-001 DS102, a placebo-controlled molecule product that can be administered orally for young adults and adolescents with Down syndrome, clinical trials are currently in progress for Down Syndrome. The firm has a wholly owned subsidiary in Melbourne, Australia.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount Project Title
2013 2 NIH $2,248,976
Translating Innovative Research Discoveries to a Potential Therapeutic for Down S

Key People / Management

  Lyndon Lien -- President & Chief Executive Officer

  Craig Garner -- Co-Founder

  Annette Madrid -- Chief Medical Officer

  Elizabeth Keith Messersmith -- Vice President, R&D Operations

  Daniel Wetmore -- Co-Founder